{"genes":["epidermal growth factor receptor","EGFR","tyrosine kinase","EGFR mutations","EGFRm","LM）是晚期非小细胞肺癌（non","3例患者均为肺腺癌，且表皮生长因子受体（epidermal growth factor receptor","EGFR）21外显子L858R突变","）。除了1例肺癌和LM同时诊断，2例分别在EGFR酪氨酸激酶抑制剂（tyrosine kinase","TKIs）和化疗进展后出现LM","，肺癌到LM平均确诊时间为8.5个月。3例患者脑增强磁共振成像","MRI）均显示软脑膜线性强化；3例脑脊液中找到癌细胞，其中2例行EGFR检测","21外显子L858R突变。2例患者接受TKIs治疗，症状好转，其中1例联合替莫唑胺","，无进展生存期","EGFRm肺腺癌可能易出现LM；NSCLC-LM症状不典型，易漏诊、误诊；TKIs联合替莫唑胺可能是EGFRm-NSCLC-LM的治疗选择"],"organisms":["6755","9606"],"publicationTypes":["English Abstract","Journal Article"],"abstract":"Leptomeningeal metastases (LM) is one of the most serious complications of advanced non-small cell lung cancer (NSCLC) due to the lower quality of life and poor prognosis. The aim of this study is to analyze the clinicopathological features and prognosis of patients with LM from NSCLC (NSCLC-LM).\nClinical data of 3 patients with NSCLC-LM collected from January 2015 to June 2016 were analyzed with a brief review.\nAll 3 patients had adenocarcinoma histology harboring epidermal growth factor receptor (EGFR) exon 21 point mutations (m). Of the 3 cases, 1 was male, 2 were female. The mean age was 61.3 years (range, 59-64 years). The main clinical manifestations and positive physical examination included headache (3/3), dizziness (3/3), nausea (3/3) and vomiting (3/3), epilepsy (2/3), diplopia (1/3), hearing loss (1/3) and meningeal stimulation sign (3/3). The median time from symptom to diagnosis of LM was 2.3 months (range, 1 to 4 months). Except 1 patient with lung cancer and LM diagnosised at the same time, the other 2 cases received the diagnosis of LM after tyrosine kinase inhibitors (TKIs) therapy or chemotherapy respectively, the median time from diagnosis of NSCLC to LC was 8.5 months. The brain enhanced magnetic resonance imaging (MRI) manifestations of all 3 cases revealed linear meningeal enhancement. Cerebrospinal fluid in 3 cases were positive cytology in whom two cases had EGFR exon 21 L858R mutations, consistenting with the lung tissue. The symptom of the 2 cases improved after TKIs therapy, and temozolomide was used as supplement of 1 case of which the progression-free survival (PFS) and overall survival (OS) was 4.9 months and 13.9 months respectively.\nLung adenocarcinoma with sensitive EGFR mutations are likely to appear LM. Lacking of typical symptoms, NSCLC-LM was easily to be missed and misdiagnosed. TKIs therapy combined with temozolomide may be effective therapies for EGFRm-NSCLC-LM patients.\u2029.\n背景与目的 脑膜转移（leptomeningeal metastasis, LM）是晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）严重并发症之一，生活质量降低，预后差。本研究旨在探讨NSCLC-LM患者的临床病理特征及预后。方法 回顾性分析2015年1月-2016年6月首都医科大学附属北京朝阳医院收治的3例NSCLC-LM患者的临床资料，并结合文献进行分析。结果 3例患者均为肺腺癌，且表皮生长因子受体（epidermal growth factor receptor, EGFR）21外显子L858R突变（mutations，m），其中男性1例，女性2例；年龄59岁-64岁，平均年龄61.3岁，主要临床表现及查体：头痛（3/3）、头晕（3/3）、恶心呕吐（3/3）、癫痫（2/3）、复视（1/3）、听力下降（1/3）、脑膜刺激征（3/3）。出现症状到LM确诊时间为1个月-4个月（平均2.3个月）。除了1例肺癌和LM同时诊断，2例分别在EGFR酪氨酸激酶抑制剂（tyrosine kinase inhibitors, TKIs）和化疗进展后出现LM，肺癌到LM平均确诊时间为8.5个月。3例患者脑增强磁共振成像（magnetic resonance imaging, MRI）均显示软脑膜线性强化；3例脑脊液中找到癌细胞，其中2例行EGFR检测，均为EGFR 21外显子L858R突变。2例患者接受TKIs治疗，症状好转，其中1例联合替莫唑胺，无进展生存期（progression-free survival, PFS）达4.9个月，总生存时间（overall survival, OS）为13.9个月。结论 EGFRm肺腺癌可能易出现LM；NSCLC-LM症状不典型，易漏诊、误诊；TKIs联合替莫唑胺可能是EGFRm-NSCLC-LM的治疗选择。.","title":"[Analysis of Clinicopathological Feature and Prognosis for \u2029Leptomeningeal Metastasis in Non-small Cell Lung Cancer].","pubmedId":"27561804"}